Biopharmaceutical CMO (Contract Manufacturing Organization) is a business that provides manufacturing services, capable of producing small quantities for preclinical research and development, as well as larger quantities required for clinical trials and commercialization. Biopharmaceutical CMOs play a crucial role in reducing overall operational risk and time to market for pharmaceutical products.
The main types of biopharmaceutical CMO products include biologics and biosimilars. Biologics encompass a diverse range of products derived from human, animal, or microbial sources, serving as medications. These substances are produced from living organisms or contain components thereof. Examples of biologic medications include vaccines, blood products, cells, allergens, genes, tissues, and recombinant proteins. Biopharmaceutical CMO products can be sourced from various origins, including mammalian and non-mammalian sources. Biopharmaceutical CMO services cover a spectrum of activities such as manufacturing, fill and finish operations, analytical and quality control studies, and packaging. These services are crucial for pharmaceutical companies looking to outsource certain aspects of their production processes, allowing them to focus on research, development, and commercialization efforts.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The biopharmaceutical CMO market research report is one of a series of new reports from The Business Research Company that provides biopharmaceutical CMO market statistics, including biopharmaceutical CMO industry global market size, regional shares, competitors with a biopharmaceutical CMO market share, detailed biopharmaceutical CMO market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical CMO industry. This biopharmaceutical CMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biopharmaceutical cmo market size has grown rapidly in recent years. It will grow from $24.81 billion in 2024 to $28.02 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, globalization, rise in healthcare expenditure, regulatory support, increased research funding.
The biopharmaceutical cmo market size is expected to see rapid growth in the next few years. It will grow to $47.79 billion in 2029 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to rise in telehealth and remote trials, global health initiatives, rise in disposable income, global health initiatives. Major trends in the forecast period include advanced therapies dominance, digitalization and industry 4.0, continuous manufacturing, sustainability and green practices.
The forecast of 14.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. drug production by driving up the cost of contract manufacturing services and purification columns sourced from India and Spain, exacerbating biologic drug shortages and increasing production costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
An increase in the strength of venture capital investments in the life science sector is expected to fuel the growth of the biopharmaceutical Contract Manufacturing Organization (CMO) market. The life sciences sector includes businesses and organizations involved in research and development related to living organisms. The strength of venture capital investments indicates how effectively a model, test, or system can operate when parameters or assumptions are changed. For example, in May 2024, the Department of Health and Social Care, a UK-based government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, representing 43% of the entire life sciences industry. Additionally, in 2024, AusBiotech, an organization based in Australia, stated that the biotechnology sector reached USD 5.66 billion (AU$8.67 billion) in total revenues by 2021, with a growth rate of 4.4%. This significant investment is anticipated to boost the manufacturing of biopharmaceuticals, contributing to the growth of the biopharmaceutical CMO market.
The increasing burden of chronic diseases is poised to fuel the growth of the biopharmaceutical CMO market. Chronic diseases, characterized by prolonged health conditions requiring ongoing medical management, represent a significant global health challenge. Biopharmaceutical CMOs play a crucial role in addressing chronic diseases by expediting drug development, ensuring cost-effective production, and maintaining high-quality standards. According to the National Library of Medicine, the US population aged 50 and older is projected to increase by 61.11% from 137.25 million in 2020 to 221.13 million in 2050, with the number of individuals with at least one chronic disease estimated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. This growing burden of chronic diseases is a key driver for the biopharmaceutical CMO market.
Technological advancement emerges as a prominent trend in the biopharmaceutical CMO market. Major companies in this sector are focusing on advancing technologies through research and development, leveraging the Internet of Things (IoT). The IoT involves the application of networked sensors and actuators for monitoring and controlling manufacturing environments. The vast amount of data generated by IoT-enabled systems can be analyzed to enhance production efficiency, automate tasks, and enable adaptable manufacturing. In February 2022, M2Cloud and Thales collaborated to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system facilitates real-time monitoring of freezers, refrigerated warehouses, and delivery boxes, ensuring temperature and position information verification. Technological advancements like these contribute to the safety and efficiency of biopharmaceutical product management, driving growth in the biopharmaceutical CMO market.
Leading companies in the biopharmaceutical CMO market are increasingly pursuing strategic partnerships to create innovative biopharmaceutical products. These collaborations enable biopharmaceutical CMO firms to pool resources and expertise, enhance research and development capabilities, broaden their market presence, and speed up commercialization. This approach ultimately fosters innovation and growth within the biopharmaceutical CMO sector. For example, in May 2024, BioConnection, a contract manufacturing company based in the Netherlands, joined forces with AGC Biologics, a contract development and manufacturing organization in the United States. Through this partnership, they aim to provide a streamlined, all-encompassing solution for biopharmaceutical development and manufacturing, thereby expediting timelines and simplifying processes for drug developers.
In May 2023, WACKER, a chemical company based in Germany, acquired ADL BioPharma for an undisclosed amount. This acquisition aims to strengthen WACKER's biotechnology operations and expand its fermentation capacities for sustainably produced food ingredients, aligning with its future growth goals. ADL BioPharma is a contract manufacturing company located in Spain that specializes in the development and production of high-quality fermentation products.
Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG
North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical CMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the biopharmaceutical CMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biopharmaceutical CMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biopharmaceutical cmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for biopharmaceutical cmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biopharmaceutical cmo market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: Biologics; Biosimilars
- 2) By Source: Mammalian; Non-Mammalian
- 3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging
- Subsegments:
- 1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies
- 2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones
- Companies Mentioned: Lonza Group AG; Fujifilm Diosynth Biotechnologies USA Inc.; Thermo Fisher Scientific Inc.; Samsung Biologics; WuXi AppTec; Catalent, Inc.; Rentschler Biopharma SE; Boehringer Ingelheim; Recipharm AB; AGC Biologics; CMC Biologics; KBI Biopharma; Vetter Pharma International GmbH; Emergent BioSolutions Inc.; Aenova Group; Synlogic, Inc.; MedImmune (AstraZeneca); BioLife Sciences; Bio-Xcellence (Boehringer Ingelheim); AbbVie Contract Manufacturing; PCI Pharma Services; AltheaDx; Daxor Corporation; Genomatica, Inc.; Astellas Pharma; Juno Therapeutics (Celgene); Medpace; Celerion; Evonik Industries AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Biopharmaceutical CMO Market Characteristics
3. Biopharmaceutical CMO Market Trends And Strategies
4. Biopharmaceutical CMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Biopharmaceutical CMO Growth Analysis And Strategic Analysis Framework
- 5.1. Global Biopharmaceutical CMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Biopharmaceutical CMO Market Growth Rate Analysis
- 5.4. Global Biopharmaceutical CMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Biopharmaceutical CMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Biopharmaceutical CMO Total Addressable Market (TAM)
6. Biopharmaceutical CMO Market Segmentation
- 6.1. Global Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Biologics
- Biosimilars
- 6.2. Global Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Mammalian
- Non-Mammalian
- 6.3. Global Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Manufacturing
- Fill And Finish Operations
- Analytical And QC Studies
- Packaging
- 6.4. Global Biopharmaceutical CMO Market, Sub-Segmentation Of Biologics, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Cell and Gene Therapies
- 6.5. Global Biopharmaceutical CMO Market, Sub-Segmentation Of Biosimilars, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Biosimilar Monoclonal Antibodies
- Biosimilar Recombinant Proteins
- Biosimilar Insulins
- Biosimilar Growth Hormones
7. Biopharmaceutical CMO Market Regional And Country Analysis
- 7.1. Global Biopharmaceutical CMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Biopharmaceutical CMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Biopharmaceutical CMO Market
- 8.1. Asia-Pacific Biopharmaceutical CMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Biopharmaceutical CMO Market
- 9.1. China Biopharmaceutical CMO Market Overview
- 9.2. China Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Biopharmaceutical CMO Market
- 10.1. India Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Biopharmaceutical CMO Market
- 11.1. Japan Biopharmaceutical CMO Market Overview
- 11.2. Japan Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Biopharmaceutical CMO Market
- 12.1. Australia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Biopharmaceutical CMO Market
- 13.1. Indonesia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Biopharmaceutical CMO Market
- 14.1. South Korea Biopharmaceutical CMO Market Overview
- 14.2. South Korea Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Biopharmaceutical CMO Market
- 15.1. Western Europe Biopharmaceutical CMO Market Overview
- 15.2. Western Europe Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Biopharmaceutical CMO Market
- 16.1. UK Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Biopharmaceutical CMO Market
- 17.1. Germany Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Biopharmaceutical CMO Market
- 18.1. France Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Biopharmaceutical CMO Market
- 19.1. Italy Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Biopharmaceutical CMO Market
- 20.1. Spain Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Biopharmaceutical CMO Market
- 21.1. Eastern Europe Biopharmaceutical CMO Market Overview
- 21.2. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Biopharmaceutical CMO Market
- 22.1. Russia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Biopharmaceutical CMO Market
- 23.1. North America Biopharmaceutical CMO Market Overview
- 23.2. North America Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Biopharmaceutical CMO Market
- 24.1. USA Biopharmaceutical CMO Market Overview
- 24.2. USA Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Biopharmaceutical CMO Market
- 25.1. Canada Biopharmaceutical CMO Market Overview
- 25.2. Canada Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Biopharmaceutical CMO Market
- 26.1. South America Biopharmaceutical CMO Market Overview
- 26.2. South America Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Biopharmaceutical CMO Market
- 27.1. Brazil Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Biopharmaceutical CMO Market
- 28.1. Middle East Biopharmaceutical CMO Market Overview
- 28.2. Middle East Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Biopharmaceutical CMO Market
- 29.1. Africa Biopharmaceutical CMO Market Overview
- 29.2. Africa Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Biopharmaceutical CMO Market Competitive Landscape And Company Profiles
- 30.1. Biopharmaceutical CMO Market Competitive Landscape
- 30.2. Biopharmaceutical CMO Market Company Profiles
- 30.2.1. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Fujifilm Diosynth Biotechnologies USA Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Samsung Biologics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. WuXi AppTec Overview, Products and Services, Strategy and Financial Analysis
31. Biopharmaceutical CMO Market Other Major And Innovative Companies
- 31.1. Catalent, Inc.
- 31.2. Rentschler Biopharma SE
- 31.3. Boehringer Ingelheim
- 31.4. Recipharm AB
- 31.5. AGC Biologics
- 31.6. CMC Biologics
- 31.7. KBI Biopharma
- 31.8. Vetter Pharma International GmbH
- 31.9. Emergent BioSolutions Inc.
- 31.10. Aenova Group
- 31.11. Synlogic, Inc.
- 31.12. MedImmune (AstraZeneca)
- 31.13. BioLife Sciences
- 31.14. Bio-Xcellence (Boehringer Ingelheim)
- 31.15. AbbVie Contract Manufacturing
32. Global Biopharmaceutical CMO Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Biopharmaceutical CMO Market
34. Recent Developments In The Biopharmaceutical CMO Market
35. Biopharmaceutical CMO Market High Potential Countries, Segments and Strategies
- 35.1 Biopharmaceutical CMO Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Biopharmaceutical CMO Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Biopharmaceutical CMO Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
